Mylan was founded in 1961 by two U.S. Army veterans wanting to help people in rural communities obtain quality, affordable medicines. Originally a distributor of others’ products in southern West Virginia, Mylan grew over time into one of the world’s largest manufacturers of generic drugs.
Generic pharmaceuticals are the same as existing approved brand-name drugs in active ingredient, dosage form, safety, strength, route of administration, quality and performance characteristics. Generic medications are just as safe and effective as their brand-name counterparts, and often cost less.
In the United States, the Office of Generic Drugs at the Food and Drug Administration follows a rigorous review process to make sure that, compared to the brand-name (or innovator) medications, the proposed generic medications:
- Contain the same active/key ingredient
- Have the same strength
- Use the same dosage form (for instance, a tablet, capsule, or liquid) and
- Use the same route of administration (for instance, oral, topical, or injectable).
FDA's review process also ensures that generic medications perform the same way in the human body and have the same intended use as the name brand medication. Healthcare professionals and consumers can be assured that FDA-approved generic drug products have met the same rigid manufacturing standards as the innovator drug. In addition, FDA inspects facilities to make certain the generic manufacturing, packaging, and testing sites pass the same quality standards as those of brand-name drugs.
Investing in R&D and Manufacturing
Generic drugmakers do invest significant sums in R&D and in manufacturing capacity. But because generics developers are not required to reproduce expensive clinical trials and seldom engage in product promotion, generic drugs typically cost far less than brand-name drugs.
Part of the Solution
Mylan knows people are concerned about the price of prescription drugs. So are we. And that’s why we continue to leverage our heritage as a generic drug manufacturer. In the United States, for example, generics filled 90% of all prescriptions dispensed in 2017, saving the country’s healthcare system billions of dollars.
To learn more about our product portfolio in the United States, click here. To learn more about our portfolio in other countries, please visit our country pages.